Results 21 to 30 of about 5,563 (240)

Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression

Journal of Hematology & Oncology, 2023
Background T cell engagers (TCEs) have been established as an emerging modality for hematologic malignancies, but solid tumors remain refractory. However, the upregulation of programmed cell death 1 (PD-1) is correlated with T cell dysfunction that ...
Ziqiang Ding, Shuyang Sun, Xuan Wang, Xiaomei Yang, Wei Shi, Xianing Huang, Shenxia Xie, Fengzhen Mo, Xiaoqiong Hou, Aiqun Liu, Xiaobing Jiang, Zhuoran Tang, Xiaoling Lu   +12 more
doaj   +2 more sources

Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager [PDF]

Journal for ImmunoTherapy of Cancer, 2019
Background Oncolytic virus (OV)-based therapies have an emerging role in the treatment of solid tumors, involving both direct cell lysis and immunogenic cell death.
Jana de Sostoa, Carlos Alberto Fajardo, Rafael Moreno, Maria D. Ramos, Martí Farrera-Sal, Ramon Alemany   +5 more
doaj   +3 more sources

DARPin-fused T cell engager for adenovirus-mediated cancer therapy [PDF]

Molecular Therapy: Oncology
Bispecific T cell engagers are a promising class of therapeutic proteins for cancer therapy. Their potency and small size often come with systemic toxicity and short half-life, making intravenous administration cumbersome.
Patrick C. Freitag, Jonas Kolibius, Ronja Wieboldt, Remi Weber, K. Patricia Hartmann, Merel van Gogh, Dominik Brücher, Heinz Läubli, Andreas Plückthun   +8 more
doaj   +2 more sources

Evaluation of Bispecific T-Cell Engagers Targeting Murine Cytomegalovirus

Viruses
Human cytomegalovirus is a ubiquitous herpesvirus that, while latent in most individuals, poses a great risk to immunocompromised patients. In contrast to directly acting traditional antiviral drugs, such as ganciclovir, we aim to emulate a physiological infection control using T cells.
Hanna Menschikowski, Christopher Bednar, Sabrina Kübel, Manuel Hermann, Larissa Bauer, Marco Thomas, Arne Cordsmeier, Armin Ensser   +7 more
openaire   +6 more sources

For whom the T cells troll? Bispecific T-cell engagers in glioblastoma [PDF]

Journal for ImmunoTherapy of Cancer, 2021
Glioblastoma is the the most common primary brain tumor in adults. Onset of disease is followed by a uniformly lethal prognosis and dismal overall survival. While immunotherapies have revolutionized treatment in other difficult-to-treat cancers, these have failed to demonstrate significant clinical benefit in patients with glioblastoma.
Kirit Singh, Kelly M Hotchkiss, Aditya A Mohan, Jessica L Reedy, John H Sampson, Mustafa Khasraw   +5 more
openaire   +3 more sources

Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma

PLoS ONE, 2022
Cholangiocarcinoma (CCA) is a lethal cancer of bile duct epithelial cells with a high mortality rate and limited therapeutic options. An effective treatment is, therefore, urgently needed to improve treatment outcomes for these patients. To develop a new
Thanich Sangsuwannukul, Kamonlapat Supimon, Thaweesak Chieochansin, Kornkan Choomee, Jatuporn Sujjitjoon, Mutita Junking, Pa-thai Yenchitsomanus   +6 more
doaj   +2 more sources

Trial Watch - bispecific T cell engagers and higher-order multispecific immunotherapeutics

OncoImmunology
Over the past decades, cancer immunotherapy has evolved into clinical practice, with bispecific T cell engagers (TCEs) and other higher-order multispecific immunotherapeutics emerging as approaches for precision immune modulation.
Enfu Xue, Xiaolian Deng, Flora Doffe, Guido Kroemer, Oliver Kepp   +4 more
doaj   +2 more sources

T-cell-engaging bispecific antibodies in cancer

The Lancet, 2023
T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T cells to the tumour, followed by T-cell activation and degranulation, and tumour cell elimination.
Niels W C J, van de Donk, Sonja, Zweegman   +1 more
openaire   +4 more sources

Bispecific T‐cell engagers for cancer immunotherapy [PDF]

Immunology & Cell Biology, 2014
Bispecific T‐cell engagers (BiTEs) are a new class of immunotherapeutic molecules intended for the treatment of cancer. These molecules enhance the patient's immune response to tumors by retargeting T cells to tumor cells. BiTEs are constructed of two single‐chain variable fragments (scFv) connected in tandem by a flexible linker. One scFv binds to a T‐
Amelia M, Huehls, Tiffany A, Coupet, Charles L, Sentman   +2 more
openaire   +2 more sources

Simultaneous evaluation of treatment efficacy and toxicity for bispecific T-cell engager therapeutics in a humanized mouse model. [PDF]

FASEB J, 2023
Immuno-oncology (IO)-based therapies such as checkpoint inhibitors, bi-specific antibodies, and CAR-T-cell therapies have shown significant success in the treat- ment of several cancer indications. However, these therapies can result in the de- velopment
Yang J, Jiao J, Draheim KM, Yang G, Yang H, Yao LC, Shultz LD, Greiner DL, Rajagopal D, Vessillier S, Maier CC, Mohanan S, Cai D, Cheng M, Brehm MA, Keck JG.   +15 more
europepmc   +4 more sources